Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β

Alzheimer's & Dementia - Tập 13 - Trang 1004-1012 - 2017
Elizabeth C. Mormino1, Kathryn V. Papp1,2, Dorene M. Rentz1,2, Michael C. Donohue3, Rebecca Amariglio1,2, Yakeel T. Quiroz1,4,5, Jasmeer Chhatwal1, Gad A. Marshall1,2, Nancy Donovan6, Jonathan Jackson1, Jennifer R. Gatchel5, Bernard J. Hanseeuw1, Aaron P. Schultz4,7, Paul S. Aisen3, Keith A. Johnson1,2,7,8, Reisa A. Sperling1,2,7
1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
3Department of Neurology, Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA
4Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA
5Department of Psychiatry, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA
6Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
7Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
8Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA

Tóm tắt

AbstractIntroduction

Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials.

Methods

We examined amyloid β (Aβ)‐related change in several variations of the preclinical Alzheimer cognitive composite (PACC) and each individual PACC component in clinically normal (CN) older participants in the Harvard Aging Brain Study. We then examined the PACC variations in the Alzheimer's Disease Cooperative Study Prevention Instrument Study as a replication cohort.

Results

Aβ+ CN individuals demonstrated longitudinal decline on all individual PACC components and all PACC variations. Aβ group differences emerged earlier when Free and Cued Selective Reminding Test Free Recall was included in the PACC. PACC decline was associated with Clinical Dementia Rating progression.

Discussion

This independent data set and a replication cohort confirm the ability of the PACC to capture both early and late cognitive decline during the preclinical stages of Alzheimer's disease, which may prove advantageous in the prevention trial design.


Tài liệu tham khảo

10.1016/S1474-4422(12)70291-0 10.1016/j.jalz.2011.03.003 10.1212/WNL.0b013e3182661f74 10.1002/ana.23650 Lim YY, 2013, Effect of amyloid on memory and non‐memory decline from preclinical to clinical Alzheimer's disease, Brain, 137, 221, 10.1093/brain/awt286 10.1212/WNL.0000000000000431 10.1001/jamaneurol.2015.3098 10.1212/WNL.0b013e31828c2fc8 10.1016/j.neurol.2013.07.017 10.3233/JAD-2011-0059 10.1126/scitranslmed.3007941 10.1056/NEJMp1302513 10.1016/j.jalz.2015.12.009 10.1001/archneurol.2009.272 10.1016/j.jalz.2014.02.002 10.1016/j.dadm.2015.11.003 10.1001/jamaneurol.2014.803 10.1177/089198879901200402 Teng EL, 1987, The Modified Mini‐Mental State (3MS) examination, J Clin Psychiatry, 48, 314 10.1002/ana.24546 10.1001/jamaneurol.2014.2031 Wechsler D, 1987, Wechsler Memory Scale‐Revised Wechsler D, 1981, WAIS‐R Manual: Wechsler Adult Intelligence Scale‐Revised 10.1016/0022-3956(75)90026-6 10.1080/01688639708403750 10.3233/JAD-150013 10.1080/87565648709540361 10.1097/WAD.0b013e3181cfc78b 10.1212/01.wnl.0000279336.36610.f7 10.1212/WNL.0b013e318245f447 10.1212/WNL.43.11.2412-a 10.1212/WNL.0b013e3182918ca6 10.1212/WNL.0b013e31828ab2c9 10.1001/archneur.57.6.808 10.1017/S1355617708080302 10.1016/j.jalz.2016.07.005 10.1038/nrneurol.2015.177 Papp KV, 2015, Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease, Neuropsychology, 30, 624, 10.1037/neu0000246 10.1007/s12031-016-0822-8 Rentz DM, 2016, The feasibility of At‐Home iPad Cognitive Testing for use in clinical trials, J Prev Alzheimers Dis, 3, 8 10.1016/S1474-4422(16)30125-9 10.1001/jamaneurol.2016.0194
Thông tin
Thông tin xuất bản

Alzheimer's & Dementia

Tập 13

1004-1012

Thông tin tác giả